Blueprint Medicines Corporation, a Delaware-based biopharmaceutical company, recently released its financial results for the year ended December 31, 2024, along with key business highlights. The ...
8 天
Zacks.com on MSNBPMC Q4 Earnings and Sales Miss Estimates, Shares DeclineBlueprint Medicines Corporation BPMC reported fourth-quarter 2024 adjusted loss of 79 cents per share, wider than the Zacks ...
Explore a rare case of systemic mastocytosis in a young adult, highlighting its role in unexplained osteoporosis and the need ...
This report highlights the diagnostic challenges of SM, emphasize its underrecognized role in osteoporosis and fragility fractures, and advocates for ...
Blueprint Medicines (BPMC) sees strong AYVAKIT growth, 2025 revenue guidance at $680M-$710M. Discover insights on their market expansion & $2B 2030 vision.
Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT ...
Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of ...
A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...
Funds from operations ("FFO”) (non-GAAP) for the quarter ended December 31, 2024 was $20.8 million, or $4.06 per diluted share, compared to $25.6 million, or $4.99 per diluted share for the quarter ...
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...
Research into how the health-related quality of life of patients with indolent systemic mastocytosis is affected is vital to disease management. Modern medicine recognizes that the overarching goal of ...
17 天
GlobalData on MSNAlys Pharmaceuticals receives regulatory approvals for alopaecia areata drug trialUS-based immuno-dermatology company Alys Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) and Health Canada for a Phase IIa trial of ALY-101 for alopaecia areata ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果